Advantage Austria Show navigation

POSSIBLE „SIGH OF RELIEVE“ FOR ALLERGY SUFFERERS:
BREAKTHROUGH WITH INNOVATIVE GRASS POLLEN ALLERGY VACCINE

2 March 2015

Biomay, an Austrian global leader in allergy immunotherapy, recently announced the successful
completion of phase IIb with its highly innovative grass pollen allergy vaccine BM32. The study was designed to show sustained alleviation of allergy symptoms over two consecutive grass pollen
seasons.

The treatment has shown to be both efficaceous and safe and was also very well tolerated by the
patients - Most side-effects were mild to moderate and resolved within a short period after drug
application.

Rainer Henning, CEO of Biomay commented: "This is a landmark in the history of allergy immunotherapy, We are very excited that we have achieved clinical proof of concept with our most advanced product BM32 which represents the first ever rationally designed grass pollen allergy vaccine. We will now undertake the necessary steps to bring this product to patients as soon as possible.“

It also bodes well for the future development of Biomay‘s products for other important allergies (in particular house dust mite, ragweed, birch pollen and cat dander) which are based on the same revolutionary technology platform. For further information please click here .

print
©©ADVANTAGE AUSTRIA